Key Points
- Hudson Vegas Investment, a major P3 Health Partners shareholder, sold 50,000 shares at an average price of $16.48 for $824,000, reducing its position by 50.53% to 48,959 shares.
- P3 Health Partners reported a quarterly loss of $0.63 per share, beating the consensus estimate of a $1.89 loss, while revenue of $386.38 million exceeded expectations of $377.80 million.
- Analysts have a consensus “Hold” rating and an average $17 price target; the stock opened at $11.69 and has traded between $1.52 and $16.89 over the past year.
P3 Health Partners Inc. (NASDAQ:PIII - Get Free Report) major shareholder Hudson Vegas Investment Spv, L sold 50,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $16.48, for a total value of $824,000.00. Following the transaction, the insider directly owned 48,959 shares of the company's stock, valued at $806,844.32. The trade was a 50.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
P3 Health Partners Price Performance
NASDAQ PIII opened at $11.69 on Thursday. The stock's 50 day simple moving average is $11.00 and its 200-day simple moving average is $6.54. The company has a market cap of $84.69 million, a PE ratio of -0.35 and a beta of 1.63. P3 Health Partners Inc. has a 1-year low of $1.52 and a 1-year high of $16.89.
P3 Health Partners (NASDAQ:PIII - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.89) by $1.26. The firm had revenue of $386.38 million for the quarter, compared to analysts' expectations of $377.80 million.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in P3 Health Partners stock. Lido Advisors LLC purchased a new position in shares of P3 Health Partners Inc. (NASDAQ:PIII - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 10,748 shares of the company's stock, valued at approximately $33,000. Lido Advisors LLC owned approximately 0.15% of P3 Health Partners at the end of the most recent reporting period. 7.75% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
PIII has been the topic of several recent research reports. Weiss Ratings raised shares of P3 Health Partners from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, May 28th. TD Cowen reiterated a "hold" rating and issued a $14.00 target price (up from $3.00) on shares of P3 Health Partners in a research report on Friday, May 22nd. Wall Street Zen raised shares of P3 Health Partners to a "hold" rating in a research note on Saturday, July 4th. UBS Group set a $14.00 price target on shares of P3 Health Partners in a research report on Friday, May 15th. Finally, Lake Street Capital reaffirmed a "buy" rating and set a $23.00 price objective on shares of P3 Health Partners in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, P3 Health Partners has a consensus rating of "Hold" and an average price target of $17.00.
Get Our Latest Stock Analysis on PIII
About P3 Health Partners
(
Get Free Report)
P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company's platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.
The company's core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
